JP2009518359A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009518359A5 JP2009518359A5 JP2008543828A JP2008543828A JP2009518359A5 JP 2009518359 A5 JP2009518359 A5 JP 2009518359A5 JP 2008543828 A JP2008543828 A JP 2008543828A JP 2008543828 A JP2008543828 A JP 2008543828A JP 2009518359 A5 JP2009518359 A5 JP 2009518359A5
- Authority
- JP
- Japan
- Prior art keywords
- quinazoline
- alkyl
- diamine
- hydrogen
- disease
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 229910052739 hydrogen Inorganic materials 0.000 claims 12
- 239000001257 hydrogen Substances 0.000 claims 12
- XELRMPRLCPFTBH-UHFFFAOYSA-N quinazoline-2,4-diamine Chemical class C1=CC=CC2=NC(N)=NC(N)=C21 XELRMPRLCPFTBH-UHFFFAOYSA-N 0.000 claims 11
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 8
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 claims 6
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 6
- 150000002431 hydrogen Chemical class 0.000 claims 4
- 150000003839 salts Chemical class 0.000 claims 4
- 201000010099 disease Diseases 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 239000000203 mixture Substances 0.000 claims 3
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 125000001424 substituent group Chemical group 0.000 claims 3
- BMVRHWVWDHESKT-KPMSDPLLSA-N (2R)-2-(1,2,3,4-tetrahydronaphthalen-1-yl)-1H-quinazoline-2,4-diamine Chemical compound C1(CCCC2=CC=CC=C12)[C@]1(NC2=CC=CC=C2C(=N1)N)N BMVRHWVWDHESKT-KPMSDPLLSA-N 0.000 claims 2
- -1 2, N 4 - bis (3,4-difluorobenzyl) quinazoline-2,4-diamine Chemical compound 0.000 claims 2
- 208000020925 Bipolar disease Diseases 0.000 claims 2
- 208000006011 Stroke Diseases 0.000 claims 2
- TTWWIRYVJKYYKS-UHFFFAOYSA-N 2-[benzyl-[4-[(4-chlorophenyl)methylamino]quinazolin-2-yl]amino]ethanol Chemical compound N=1C(NCC=2C=CC(Cl)=CC=2)=C2C=CC=CC2=NC=1N(CCO)CC1=CC=CC=C1 TTWWIRYVJKYYKS-UHFFFAOYSA-N 0.000 claims 1
- DPWSGDUKXHUVTN-UHFFFAOYSA-N 2-n,4-n-bis[(4-chlorophenyl)methyl]quinazoline-2,4-diamine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(NCC=2C=CC(Cl)=CC=2)=C(C=CC=C2)C2=N1 DPWSGDUKXHUVTN-UHFFFAOYSA-N 0.000 claims 1
- FRAFOCUMRJDYKD-UHFFFAOYSA-N 2-n-[(3,4-difluorophenyl)methyl]-4-n-[[4-(dimethylamino)phenyl]methyl]quinazoline-2,4-diamine Chemical compound C1=CC(N(C)C)=CC=C1CNC1=NC(NCC=2C=C(F)C(F)=CC=2)=NC2=CC=CC=C12 FRAFOCUMRJDYKD-UHFFFAOYSA-N 0.000 claims 1
- VFOAWDUSHZKVRP-UHFFFAOYSA-N 2-n-[(4-chlorophenyl)methyl]-4-n-(1,2,3,4-tetrahydronaphthalen-1-yl)quinazoline-2,4-diamine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(NC2C3=CC=CC=C3CCC2)=C(C=CC=C2)C2=N1 VFOAWDUSHZKVRP-UHFFFAOYSA-N 0.000 claims 1
- FWRKSDQLNYUCJB-UHFFFAOYSA-N 2-n-[[3-(aminomethyl)phenyl]methyl]-4-n-[(3,4-difluorophenyl)methyl]quinazoline-2,4-diamine Chemical compound NCC1=CC=CC(CNC=2N=C3C=CC=CC3=C(NCC=3C=C(F)C(F)=CC=3)N=2)=C1 FWRKSDQLNYUCJB-UHFFFAOYSA-N 0.000 claims 1
- QVPHXIIUCPORPG-UHFFFAOYSA-N 2-n-benzyl-4-n-[(4-chlorophenyl)methyl]-2-n-[2-(dimethylamino)ethyl]quinazoline-2,4-diamine Chemical compound N=1C(NCC=2C=CC(Cl)=CC=2)=C2C=CC=CC2=NC=1N(CCN(C)C)CC1=CC=CC=C1 QVPHXIIUCPORPG-UHFFFAOYSA-N 0.000 claims 1
- OXWIOQSMRRTMCN-UHFFFAOYSA-N 3-[benzyl-[4-[(4-chlorophenyl)methylamino]quinazolin-2-yl]amino]propanenitrile Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(N(CCC#N)CC=2C=CC=CC=2)=NC2=CC=CC=C12 OXWIOQSMRRTMCN-UHFFFAOYSA-N 0.000 claims 1
- NXEKJHORSLAWMO-UHFFFAOYSA-N 4-[(3,4-difluorophenyl)methyl]-1H-quinazoline-2,4-diamine Chemical compound N1C(N)=NC2=CC=CC=C2C1(N)CC1=CC=C(F)C(F)=C1 NXEKJHORSLAWMO-UHFFFAOYSA-N 0.000 claims 1
- 125000006283 4-chlorobenzyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1Cl)C([H])([H])* 0.000 claims 1
- 206010001497 Agitation Diseases 0.000 claims 1
- 201000004384 Alopecia Diseases 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000000044 Amnesia Diseases 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 208000019901 Anxiety disease Diseases 0.000 claims 1
- 206010003225 Arteriospasm coronary Diseases 0.000 claims 1
- 206010003591 Ataxia Diseases 0.000 claims 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 claims 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 claims 1
- 206010048994 Bladder spasm Diseases 0.000 claims 1
- 201000004569 Blindness Diseases 0.000 claims 1
- 201000006474 Brain Ischemia Diseases 0.000 claims 1
- 208000003174 Brain Neoplasms Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- 206010008120 Cerebral ischaemia Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 206010010774 Constipation Diseases 0.000 claims 1
- 206010010904 Convulsion Diseases 0.000 claims 1
- 201000003883 Cystic fibrosis Diseases 0.000 claims 1
- 206010011878 Deafness Diseases 0.000 claims 1
- 206010012289 Dementia Diseases 0.000 claims 1
- 206010012735 Diarrhoea Diseases 0.000 claims 1
- 208000005171 Dysmenorrhea Diseases 0.000 claims 1
- 206010013935 Dysmenorrhoea Diseases 0.000 claims 1
- 208000010228 Erectile Dysfunction Diseases 0.000 claims 1
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 1
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 206010062016 Immunosuppression Diseases 0.000 claims 1
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 1
- 206010065390 Inflammatory pain Diseases 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 241000124008 Mammalia Species 0.000 claims 1
- 208000026139 Memory disease Diseases 0.000 claims 1
- 208000019695 Migraine disease Diseases 0.000 claims 1
- 208000019022 Mood disease Diseases 0.000 claims 1
- 208000026072 Motor neurone disease Diseases 0.000 claims 1
- 208000008238 Muscle Spasticity Diseases 0.000 claims 1
- 206010068871 Myotonic dystrophy Diseases 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 208000002193 Pain Diseases 0.000 claims 1
- 208000018737 Parkinson disease Diseases 0.000 claims 1
- 206010054048 Postoperative ileus Diseases 0.000 claims 1
- 208000005107 Premature Birth Diseases 0.000 claims 1
- 206010036590 Premature baby Diseases 0.000 claims 1
- 208000028017 Psychotic disease Diseases 0.000 claims 1
- 208000003782 Raynaud disease Diseases 0.000 claims 1
- 208000012322 Raynaud phenomenon Diseases 0.000 claims 1
- 208000036071 Rhinorrhea Diseases 0.000 claims 1
- 206010039101 Rhinorrhoea Diseases 0.000 claims 1
- 208000021386 Sjogren Syndrome Diseases 0.000 claims 1
- 208000030886 Traumatic Brain injury Diseases 0.000 claims 1
- 206010046543 Urinary incontinence Diseases 0.000 claims 1
- 208000025609 Urogenital disease Diseases 0.000 claims 1
- 206010047163 Vasospasm Diseases 0.000 claims 1
- 230000003187 abdominal effect Effects 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 231100000360 alopecia Toxicity 0.000 claims 1
- 230000036506 anxiety Effects 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 claims 1
- 208000028683 bipolar I disease Diseases 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 206010008118 cerebral infarction Diseases 0.000 claims 1
- 208000010877 cognitive disease Diseases 0.000 claims 1
- 206010009887 colitis Diseases 0.000 claims 1
- 230000036461 convulsion Effects 0.000 claims 1
- 208000029078 coronary artery disease Diseases 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 230000006735 deficit Effects 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 206010013781 dry mouth Diseases 0.000 claims 1
- 206010015037 epilepsy Diseases 0.000 claims 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 claims 1
- 230000005176 gastrointestinal motility Effects 0.000 claims 1
- 230000010370 hearing loss Effects 0.000 claims 1
- 231100000888 hearing loss Toxicity 0.000 claims 1
- 208000016354 hearing loss disease Diseases 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims 1
- 201000008980 hyperinsulinism Diseases 0.000 claims 1
- 230000001506 immunosuppresive effect Effects 0.000 claims 1
- 201000001881 impotence Diseases 0.000 claims 1
- 208000035231 inattentive type attention deficit hyperactivity disease Diseases 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000002551 irritable bowel syndrome Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 208000017169 kidney disease Diseases 0.000 claims 1
- 230000006984 memory degeneration Effects 0.000 claims 1
- 206010027175 memory impairment Diseases 0.000 claims 1
- 208000023060 memory loss Diseases 0.000 claims 1
- 206010027599 migraine Diseases 0.000 claims 1
- 208000005264 motor neuron disease Diseases 0.000 claims 1
- 201000006938 muscular dystrophy Diseases 0.000 claims 1
- 208000031225 myocardial ischemia Diseases 0.000 claims 1
- 230000003274 myotonic effect Effects 0.000 claims 1
- YJZPWKBXNDNIPD-UHFFFAOYSA-N n-[(4-chlorophenyl)methyl]-2-(2-phenylpiperidin-1-yl)quinazolin-4-amine Chemical compound C1=CC(Cl)=CC=C1CNC1=NC(N2C(CCCC2)C=2C=CC=CC=2)=NC2=CC=CC=C12 YJZPWKBXNDNIPD-UHFFFAOYSA-N 0.000 claims 1
- SYSQUGFVNFXIIT-UHFFFAOYSA-N n-[4-(1,3-benzoxazol-2-yl)phenyl]-4-nitrobenzenesulfonamide Chemical class C1=CC([N+](=O)[O-])=CC=C1S(=O)(=O)NC1=CC=C(C=2OC3=CC=CC=C3N=2)C=C1 SYSQUGFVNFXIIT-UHFFFAOYSA-N 0.000 claims 1
- 201000003631 narcolepsy Diseases 0.000 claims 1
- 208000004296 neuralgia Diseases 0.000 claims 1
- 208000021722 neuropathic pain Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 208000030761 polycystic kidney disease Diseases 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 208000020016 psychiatric disease Diseases 0.000 claims 1
- 230000028327 secretion Effects 0.000 claims 1
- 201000002859 sleep apnea Diseases 0.000 claims 1
- 208000019116 sleep disease Diseases 0.000 claims 1
- 208000020685 sleep-wake disease Diseases 0.000 claims 1
- 208000018198 spasticity Diseases 0.000 claims 1
- 230000009529 traumatic brain injury Effects 0.000 claims 1
- 206010044652 trigeminal neuralgia Diseases 0.000 claims 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA200501732 | 2005-12-07 | ||
| US74822105P | 2005-12-08 | 2005-12-08 | |
| PCT/EP2006/069380 WO2007065913A1 (en) | 2005-12-07 | 2006-12-06 | Novel quinazoline-2,4-diamine derivatives and their use as modulators of small-conductance calcium-activated potassium channels |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009518359A JP2009518359A (ja) | 2009-05-07 |
| JP2009518359A5 true JP2009518359A5 (enExample) | 2010-01-14 |
Family
ID=37814475
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2008543828A Abandoned JP2009518359A (ja) | 2005-12-07 | 2006-12-06 | 新規なキナゾリン−２，４−ジアミン誘導体及び小コンダクタンスカルシウム依存性カリウムチャネルの調節剤としてのそれらの使用 |
Country Status (3)
| Country | Link |
|---|---|
| EP (1) | EP1963284A1 (enExample) |
| JP (1) | JP2009518359A (enExample) |
| WO (1) | WO2007065913A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010051819A1 (en) * | 2008-11-10 | 2010-05-14 | Neurosearch A/S | Novel 2,3-diamino-quinazolinone derivatives and their medical use |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL89027A (en) * | 1988-01-29 | 1993-01-31 | Lilly Co Eli | Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them |
| ATE121735T1 (de) * | 1991-02-20 | 1995-05-15 | Pfizer | 2,4-diaminochinazolin-derivate, um die antitumorwirkung zu erhöhen. |
| WO2003055866A1 (en) * | 2001-12-21 | 2003-07-10 | Bayer Pharmaceuticals Corporation | Quinazoline and quinoline derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents |
| AU2003255482A1 (en) * | 2002-10-02 | 2004-04-23 | Merck Patent Gmbh | Use of 4 amino-quinazolines as anti cancer agents |
| US20040092739A1 (en) * | 2002-11-13 | 2004-05-13 | Zejun Xiao | Process for synthesizing antifolates |
| WO2005011758A2 (en) * | 2003-07-25 | 2005-02-10 | Ciba Specialty Chemicals Holding Inc. | Use of substituted 2,4-bis (alkylamino) pyrimidines or -quinazolines as antimicrobials |
| CN101031551A (zh) * | 2004-07-06 | 2007-09-05 | 安吉永生物制药公司 | 针对癌症治疗的肝细胞生长因子/c－met活性的喹唑啉调节剂 |
-
2006
- 2006-12-06 WO PCT/EP2006/069380 patent/WO2007065913A1/en not_active Ceased
- 2006-12-06 EP EP06830421A patent/EP1963284A1/en not_active Withdrawn
- 2006-12-06 JP JP2008543828A patent/JP2009518359A/ja not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2008526815A5 (enExample) | ||
| US8058474B2 (en) | Urea derivative and process for preparing the same | |
| JP2009519995A5 (enExample) | ||
| US8580960B2 (en) | Process for synthesis of phenoxy diaminopyrimidine derivatives | |
| JP2008543915A5 (enExample) | ||
| JP2007509043A5 (enExample) | ||
| CN101103034A (zh) | 抑制β-分泌酶的氨基-咪唑酮 | |
| JP2009024025A (ja) | テモゾロミドおよびアナログの合成 | |
| IL234135A (en) | Processes for Preparing (3) –1– (s– Ethoxy – 4 – Methoxyphenyl) –2 – Methanesulfonylethylamine | |
| CN1630648A (zh) | N－苯基－2－嘧啶胺衍生物 | |
| JP2008534472A5 (enExample) | ||
| CN1137878C (zh) | 芳氧基苯胺衍生物 | |
| JP2011518866A (ja) | ５−（２−アミノ−ピリミジン−４−イル）−２−アリール−ｌＨ−ピロール−３−カルボキサミドの製造方法 | |
| JP5595404B2 (ja) | 光学活性（ｓ）−（−）−２−（ｎ−プロピルアミノ）−５−メトキシテトラリン及び（ｓ）−（−）−２−（ｎ−プロピルアミノ）−５−ヒドロキシテトラリン化合物の調製の方法 | |
| JP2009542602A5 (enExample) | ||
| JP2010502674A5 (enExample) | ||
| CN103857672A (zh) | 用于制备1-(4-(4-(3,4-二氯-2-氟苯氨基)-7-甲氧基喹唑啉-6-基氧基)哌啶-1-基)-丙-2-烯-1-酮盐酸盐的方法及其中使用的中间产物 | |
| JP2009518359A5 (enExample) | ||
| JP2009511548A5 (enExample) | ||
| JP4397693B2 (ja) | Ｎ１−（２’−ピリジル）−１，２−アルカンジアミンスルファミン酸の合成および生物学的に活性なピペラジンの合成におけるその使用 | |
| JP2009530352A5 (enExample) | ||
| CN1288153C (zh) | 2－氨基－4－吡啶基甲基－二氢噻唑衍生物作为诱导型no－合酶抑制剂的用途 | |
| US8378119B2 (en) | Method for producing asymmetric tetrasubstituted carbon atom-containing compound | |
| JP2010509249A5 (enExample) | ||
| JP4820873B2 (ja) | アリールオキシジアミノピリミジンの合成方法 |